Home > Healthcare > Psoriatic Arthritis Treatment Market > Table of Contents

Psoriatic Arthritis Treatment Market - By Drug Type (NSAIDs, DMARDs [Synthetic, Biologics], Biological Agents [TNF, IL-17, IL-23]), Route of Administration, Medication Type, Age Group, Distribution Channel – Global Forecast (2024 – 2032)

  • Report ID: GMI9864
  • Published Date: Jun 2024
  • Report Format: PDF

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Increasing prevalence of psoriatic arthritis

3.2.1.2    Expanding R&D funding and activities

3.2.1.3    Growing awareness and diagnosis

3.2.1.4    Improved diagnostic technologies

3.2.2    Industry pitfalls & challenges

3.2.2.1    Side effects and adverse reactions

3.2.2.2    Regulatory challenges

3.3    Growth potential analysis

3.4    Pipeline analysis

3.5    Regulatory landscape

3.6    Porters analysis

3.7    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company matrix analysis

4.3    Company market share analysis

4.4    Competitive analysis of major market players

4.5    Competitive positioning matrix

4.6    Strategy dashboard

Chapter 5   Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Nonsteroidal anti-inflammatory drugs (NSAIDs)

5.3    Disease-modifying antirheumatic drugs (DMARDs)

5.4    Biological agents

5.4.1    TNF inhibitors

5.4.2    IL-17 inhibitors

5.4.3    IL-12/23 inhibitors

5.5    Other drug types

Chapter 6   Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Topical

6.3    Oral

6.4    Injectable

Chapter 7   Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    Branded

7.3    Generics

Chapter 8   Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)

8.1    Key trends

8.2    below 18 years

8.3    19-40

8.4    41-60

8.5    61 above

Chapter 9   Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)

9.1    Key trends

9.2    Hospital pharmacies

9.3    Retail pharmacies

9.4    Online pharmacies

Chapter 10   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

10.1   Key trends

10.2   North America

10.2.1    U.S.

10.2.2    Canada

10.3   Europe

10.3.1    Germany

10.3.2    UK

10.3.3    France

10.3.4    Spain

10.3.5    Italy

10.3.6    Netherlands

10.3.7    Rest of Europe

10.4   Asia Pacific

10.4.1    Japan

10.4.2    China

10.4.3    India

10.4.4    Australia

10.4.5    South Korea

10.4.6    Rest of Asia Pacific

10.5   Latin America

10.5.1    Brazil

10.5.2    Mexico

10.5.3    Rest of Latin America

10.6   Middle East and Africa

10.6.1    Saudi Arabia

10.6.2    South Africa

10.6.3    UAE

10.6.4    Rest of Middle East and Africa

Chapter 11   Company Profiles

11.1   Abbvie Inc.

11.2   Amgen Inc.

11.3   Biogen

11.4   Bristol-Myers Squibb Company

11.5   Eli Lilly and Company

11.6   Fujifilm Kyowa Kirin Biologics Co., Ltd.

11.7   Janssen Pharmaceutical Companies (Johnson and Johnson)

11.8   Merck KGA

11.9   Novartis AG

11.10   Pfizer Inc.

11.11   Samsung Bioepis Co., Ltd.

11.12   Sanofi

11.13   Sun Pharmaceutical Industries Ltd.

11.14   Teva Pharmaceuticals Industries Ltd.

11.15   UCB S.A
 

Authors: Mariam Faizullabhoy, Gauri Wani

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 277
  • Countries covered: 22
  • Pages: 160
 Download Free Sample